中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
Apr 13,2022
13
April 2022
AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Apr 13,2022
13
April 2022
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
Feb 15,2022
15
February 2022
AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
Jan 19,2022
19
January 2022
AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients
Jan 11,2022
11
January 2022
AffaMed Technologies Announces Successful Completion of First Patient Implantations of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in Boao, Hainan
<<
<
1
2
3
4
5
6
7
>
>>
上一页
下一页
